LYRA suspends at-the-market offering, curbing near-term dilution

Rhea-AI Filing Summary

Lyra Therapeutics, Inc. (ticker: LYRA) filed a Rule 424(b)(5) prospectus supplement dated June 26, 2025 that updates its April 1, 2024 at-the-market (ATM) offering documents.

The company has been selling common stock through Cantor Fitzgerald & Co. under an Amended and Restated Controlled Equity Offering Sales Agreement. To date, 7,059,228 shares have been issued, generating aggregate gross proceeds of $24,835,145.28.

This supplement’s sole purpose is to suspend the ATM Program and terminate the continuous offering effective June 26, 2025. No further shares will be sold under the existing prospectus until the company files a new supplement. Importantly, the underlying Sales Agreement with Cantor remains in full force, preserving the framework for potential future issuances.

The U.S. Securities and Exchange Commission has neither approved nor disapproved the securities described. All other terms and disclosures in the April 1, 2024 Base Prospectus and prior supplement remain unchanged unless expressly superseded herein.

Positive

• Near-term dilution ceases because no additional shares will be sold until a new prospectus supplement is filed.

Negative

• Equity capital-raising channel paused, potentially reducing immediate financial flexibility until a new filing is made.

Insights

Financial Analyst

TL;DR: ATM suspended; dilution stops but capital-raising channel paused—overall neutral.

Selling 7.1 million shares for roughly $24.8 million indicates Lyra has already tapped its ATM facility for modest liquidity. Halting the program eliminates incremental dilution in the near term, a modest positive for existing shareholders. However, pausing sales also removes an on-demand financing option, potentially limiting balance-sheet flexibility until a new supplement is filed. Because the Sales Agreement itself remains valid, management retains the ability to resume once market conditions or capital needs warrant. Net impact is neutral: investors gain dilution relief but lose immediate ATM access.

Corporate Finance Specialist

TL;DR: Suspension signals strategic pause; no material change to financing capacity—impact neutral.

The filing is procedural. Regulatory compliance requires a fresh prospectus supplement after a defined issuance period or material update. By suspending the ATM effective June 26, 2025, Lyra ensures its disclosure remains current. The company can still raise equity quickly by issuing a new supplement, as the Cantor agreement persists. Absence of further detail on cash runway or alternative financing means investors cannot gauge funding sufficiency from this document alone. Accordingly, the event is administratively important but not fundamentally transformative.

As Filed Pursuant to Rule 424(b)(5)
Registration No. 333-278163

PROSPECTUS SUPPLEMENT

(To Prospectus and Prospectus Supplement dated

April 1, 2024)

 

Common Stock

 

 

This prospectus supplement (the “Prospectus Supplement”) supplements the prospectus dated April 1, 2024 (the “Base Prospectus”) and the prospectus supplement dated April 1, 2024 (together with the Base Prospectus, the “ATM Prospectus”), relating to the offer and sale of shares of our common stock from time to time pursuant to the terms of the Amended and Restated Controlled Equity Offering^SM Sales Agreement, dated March 22, 2024 (the “Agreement”), with Cantor Fitzgerald & Co. (“Cantor”) as sales agent. This Prospectus Supplement should be read in conjunction with the ATM Prospectus. This Prospectus Supplement is qualified by reference to the ATM Prospectus, except to the extent that the information presented herein supersedes the information contained in the ATM Prospectus.

In accordance with the terms of the Agreement, we may offer and sell shares of our common stock from time to time through Cantor pursuant to at-the-market transactions, subject to the limitations described in the ATM Prospectus (the “ATM Program”). As of the date of this Prospectus Supplement, we have sold an aggregate of 7,059,228 shares of our common stock pursuant to the Agreement for aggregate gross proceeds of $24,835,145.28.

The purpose of this Prospectus Supplement is to suspend the ATM Program and to terminate the continuous offering by us under the ATM Prospectus effective on June 26, 2025. We will not make any sales of our common stock pursuant to the Agreement unless and until a new prospectus supplement is filed with the Securities and Exchange Commission. However, for the avoidance of doubt, the Agreement remains in full force and effect.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

 

 

The date of this prospectus supplement is June 26, 2025.

FAQ

How many LYRA shares were sold under the ATM program to date?

7,059,228 common shares have been issued through Cantor Fitzgerald.

What total proceeds did Lyra Therapeutics raise through the ATM?

Gross proceeds amount to $24,835,145.28.

When does the suspension of the ATM Program become effective?

The suspension is effective on June 26, 2025.

Can Lyra resume sales under the existing Sales Agreement?

Yes. The Agreement remains in force, but no sales can occur until a new prospectus supplement is filed with the SEC.

Does the SEC approval status change with this supplement?

No. The SEC has neither approved nor disapproved the securities; that status is unchanged.